Predictive Oncology
AI-driven personalized cancer therapy developer, Predictive Oncology, innovates targeted treatments via data-rich patient tumors.
Founded
2002AI-driven personalized cancer therapy developer, Predictive Oncology, innovates targeted treatments via data-rich patient tumors.
Predictive Oncology, founded with a mission to revolutionize cancer treatment, leverages artificial intelligence to personalize therapies based on data from patient tumors. The company operates through three segments—Skyline, Helomics, and Soluble Biotech—and includes four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. These divisions work collaboratively to enhance drug discovery and development, focusing on improving clinical trial success rates and developing targeted therapies in partnership with pharmaceutical companies.
Notable figures affiliated with Predictive Oncology include experts in AI and oncology, though specific names are not provided. The company has achieved significant milestones in integrating machine learning with scientific research, thereby advancing the precision and efficacy of cancer treatments. Its impact is evident in its collaborations with biopharma partners and its contributions to pre-clinical drug discovery, positioning Predictive Oncology as a key player in the personalized medicine landscape.
Companies similar to Predictive Oncology include OncoPrecision, Precision Health AI, Onc.AI and Helomics.
Predictive Oncology was founded in 2002.
Predictive Oncology's headquarters is located in Eagan, MN, US.
Predictive Oncology's most recent funding round was for $21.3M (USD) in June 2021.
As of Jun 14, 2021, Predictive Oncology has raised a total of $77.6M (USD).
Predictive Oncology has 31 employees as of Feb 6, 2024.
Onc.AI
onc.ai
